Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

AstraZeneca

Johnson & Johnson

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates expressed optimism on the efficacy of COVID-19 vaccines made by various drugmakers in an interview with CNN on Sunday. What Happened: The billionaire told CNN's Fareed Zakaria that while vaccines from Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) have already shown effectiveness against COVID-19 in early data, he expects similar results from AstraZeneca Plc (NYSE: AZN), Johnson & Johnson (NYSE: JNJ) and Novavax, Inc (NASDAQ: NVAX) vaccines.

Bill Gates Says AstraZeneca, Johnson & Johnson, Novavax COVID-19 Vaccines All Likely To Prove 'Very Efficacious And Safe' By February

BioNTech SE

Moderna

Pfizer

Here are ideas for both conservative and aggressive investors.

Top COVID Vaccine Stocks to Buy Now

Pfizer and Moderna have reported vaccine efficacy of over 90%. What should Novavax investors expect?

What Are the Odds That Novavax's Coronavirus Vaccine Is 90% Effective?

Abbott Labs

At least two of them could have significant catalysts on the way this month.

3 Top Coronavirus Stocks to Buy in November

Owners of NVAX stock should not be discouraged by the recent positive results by vaccine makers Pfizer and Moderna. The post Vaccines Aren't Winner-Take-All, Making Novavax Stock a Smart Covid Play appeared first on InvestorPlace.

Vaccines Aren't Winner-Take-All, Making Novavax Stock a Smart Covid Play

As rival coronavirus vaccines generate exciting headlines, NVAX stock has fallen out of favor with Wall Street. However, this is a mistake as Novavax's vaccine candidate offers a superior holistic solution.

The Red Ink on Novavax Only Hides Its True Potential

GlaxoSmithKline

Sanofi

Dr. Angela Rasmussen explains why news from mRNA vaccine trials is so promising and shares tips for investors thinking about buying stocks like Pfizer and Moderna.

A Virologist Explains: mRNA Coronavirus Vaccines And What Investors Should Know

Adaptive Biotechnologies

bluebird bio

Blueprint Medicines

Roche Holding AG

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

5 Under-the-Radar Tickers That Will Stomp the Market in 2021

NVAX stock has a nearly $6 billion market cap based on a COVID-19 vaccine that may not work. The firm has a history of cashing in on hype.

Sell Novavax Stock After Its Huge Gain

Investors are worried that Moderna's good news could be bad news for these coronavirus vaccine leaders.

Why Pfizer, BioNTech, and Novavax Stocks Are Sinking Today

Sorrento Therapeutics Inc

Novavax and Sorrento Therapeutics have been on a sharp downward trajectory.

Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain?

Investing Tips for Buying Coronavirus Vaccine Stocks

Should You Buy a Basket of Late-Stage Coronavirus Vaccine Stocks?

Takeda Pharmaceutical

The numbers are close, but two players stand out at the moment.

Which Coronavirus Vaccine Maker Is Poised to Be the Top Supplier?

The biotech is trying to rewrite its rocky history with a little help from $2 billion in funding for a coronavirus vaccine.

Is Novavax a Ticking Time Bomb for Investors?

Novavax made a valiant effort at developing the leading Covid-19 vaccine, but it fell short. Now poor earnings will sink NVAX stock.

With Pfizer Winning the Vaccine Race, Novavax Is a Strong Sell

Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well.

Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates

Novavax to host live Q&A due to technical difficulties during quarterly call Novavax to host live Q&A due to technical difficulties during quarterly call

Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020

Novavax delivered good news Nov. 9. It announced its Covid-19 vaccine's been fast-tracked by the FDA.

Novavax Steals Some of Pfizer's Thunder With Fast Track Designation

What is a big deal for the biotech is what happens next with its COVID-19 vaccine candidate.

Novavax Didn't Come Close to Analysts' Q3 Estimates -- and It's No Big Deal

Novavax, Inc. (NVAX) CEO Stan Erck on Q3 2020 Results - Earnings Call Transcript

GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2020.

Novavax Reports Third Quarter 2020 Financial and Operational Results

NVAX stock has promise after Phase 3 data is released, but investors will have to be ready and willing to play the long game. The post Don't Expect Massive Short-Term Gains in Novavax Stock Right Now appeared first on InvestorPlace.

Don't Expect Massive Short-Term Gains in Novavax Stock Right Now

The US Food and Drug Administration has granted “fast track” status to Novavax's experimental coronavirus vaccine, the company announced Monday. The designation will allow the Maryland-based biotech firm to submit its application for regulatory approval piecemeal as data becomes available — rather than waiting to compile all the results before submitting the application.

Novavax COVID vaccine gets ‘fast track' status from FDA

Many traders have been counting on NVAX stock to be the winner of the Covid-19 vaccine race. Their argument just got a lot stronger.

News for Novavax Stock (NVAX)